Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a potent, irreversible, specific BTK inhibitor that inhibits the ibrutinib‐resistant C481S BTK with nanomolar potency. ZYBT1 is found to be a promising molecule to treat both cancer and RA. In the present report we profiled the molecule for in‐vitro, in‐vivo activity, and pharmacokinetic properties. ZYBT1 inhibits BTK and C481S BTK with an IC
50
of 1 nmol/L and 14 nmol/L, respectively, inhibits the growth of various leukemic cell lines with IC
50
of 1 nmol/L to 15 μmol/L, blocks the phosphorylation of BTK and PLCγ2, and inhibits secretion of TNF‐α, IL‐8 and IL‐6. It has favorable pharmacokinetic properties suitable for using as an oral anti‐cancer and anti‐arthritic drug. In accordance with the in‐vitro properties, it demonstrated robust efficacy in murine models of collagen‐induced arthritis (CIA) and streptococcal cell wall (SCW) induced arthritis. In both models, ZYBT1 alone could suppress the progression of the diseases. It also reduced the growth of TMD8 xenograft tumor. The results suggested that ZYBT1 has high potential for treating RA, and cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.